Evaluate the Immunogenicity of a Novel Glucagon Formulation

Clinical trial NCT01959334 · COMPLETED

Trial details

NCT number: NCT01959334
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Drug-specific Antibodies Diabetes Mellitus

Start date: 2013-09-01
Primary completion: 2013-12-01
Enrollment: 75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.